Another TRPV1 agonist, resiniferatoxin was shown to be effective in controlling the motor symptoms in the AAV-A53T knock-in PD mouse model (Sorrento Therapeutics Inc, 2020). This evidence concerns the gene TRPV1 and Parkinson disease.